NYSE:LLY 23 December 2025 - 1 January 2026

Drugmakers plan to raise U.S. list prices on at least 350 branded medicines in 2026, according to data from healthcare research firm 3 Axis Advisors. The median increase is about 4%, and the figures do not reflect rebates or other discounts. The same dataset showed drugmakers also plan to cut list prices on about nine medicines, including a more than 40% reduction for diabetes drug Jardiance, sold by Boehringer Ingelheim and Eli Lilly, after Medicare negotiated a lower price for 2026. Reuters

Eli Lilly shares slipped 0.5% in Wednesday’s final session of 2025, closing at $1,074.68, before U.S. markets shut for the New Year’s Day holiday. StockAnalysis+1

Eli Lilly shares ended the holiday week little changed after South Korean biotech ABL Bio said it would receive $55 million in funding from the U.S. drugmaker under a research collaboration. PR Newswire

Eli Lilly and Company heads into the final trading stretch of 2025 with its stock near record territory and investors laser-focused on three forces that can move the shares quickly: the accelerating battle for obesity and diabetes drug dominance, the policy and pricing machinery starting to reshape access to GLP‑1 treatments, and Lilly’s pipeline and business-development cadence beyond today’s blockbusters.

New York — As of 7:56 p.m. ET on Friday, December 26, 2025, Eli Lilly and Company is coming off a session that left the stock hovering around $1,077.75, essentially flat on the day after a narrow trading range.

New York — Friday, December 26, 2025: Eli Lilly and Company is trading near $1,075 per share, essentially flat to slightly lower on the day in a thin, post‑Christmas U.S. session where the major indexes are hovering close to record levels. Reuters

Eli Lilly and Company heads into the Friday, Dec. 26, 2025 U.S. market open with investors balancing two powerful forces: policy-driven price pressure on GLP‑1 drugs and pipeline-driven growth potential that keeps Lilly at the center of the obesity and diabetes mega-trend.